ClinVar Miner

Submissions for variant NM_000155.4(GALT):c.292G>C (p.Asp98His) (rs111033670)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000790788 SCV000330952 pathogenic not provided 2015-11-25 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000022080 SCV000695687 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2016-08-10 criteria provided, single submitter clinical testing Variant summary: The GALT c.292G>C (p.Asp98His) variant involves the alteration of a non-conserved nucleotide. The altered amino acid Asp98 is located in Galactose-1-phosphate uridyl transferase, N-terminal dormain and HIT-like domain. 4/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 1/121426 control chromosomes at a frequency of 0.0000082, which does not exceed the estimated maximal expected allele frequency of a pathogenic GALT variant (0.0028868). It was reported in patients with hereditary galactosemia and proven reduced enzyme activity (less than 10% of the WT enzyme) suggesting pathogenicity. Moreover, another variant affecting the same residue, p.Asp98Asn has been reported to be associated with galactosemia indicating the variant to be located in a mutational hotspot and the clinical importance of the Asp98 residue. In addition, a clinical diagnostic laboratory classified the variant as pathogenic via ClinVar. Taken together, this variant is classified as pathogenic.
Invitae RCV000022080 SCV000755879 uncertain significance Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2017-11-13 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid with histidine at codon 98 of the GALT protein (p.Asp98His). The aspartic acid residue is highly conserved and there is a moderate physicochemical difference between aspartic acid and histidine. This variant is present in population databases (rs111033670, ExAC no frequency). This variant has not been reported in the literature in individuals with GALT-related disease. ClinVar contains an entry for this variant (Variation ID: 25149). Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). A different missense substitution at this codon (p.Asp98Asn) has been determined to be pathogenic (PMID: 12595586, 10408771, 22743281). This suggests that the aspartic acid residue is critical for GALT protein function and that other missense substitutions at this position may also be pathogenic. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Research and Development, ARUP Laboratories RCV000022080 SCV000042756 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2012-12-04 no assertion criteria provided clinical testing Converted during submission to Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.